Compare Hims and Hers Health Inc (HIMS) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Roundhill Magnificent Seven ETF — how do they compare? Hims and Hers Health Inc trades at $29.35 (market cap $6.55B), while Roundhill Magnificent Seven ETF trades at $73.72 (market cap $5.78B). The key difference: Hims and Hers Health Inc and Roundhill Magnificent Seven ETF are close in size by market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| HIMS | MAGS | |
|---|---|---|
Market Cap | $6.55B | $5.78B |
Volume | 14,842,814 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $62.76 | $73.90 |
52-Week Low | $14.52 | $55.39 |
Typical Hold Time | 21 Days | 36 Days |
Enterprise Value | $7.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.63, down slightly by 0.08% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights ongoing investor debate about the Magnificent Seven's leadership role amid shifting AI investment trends.
The ETF faces near-term pressure from underperformance versus the S&P 500 but maintains long-term growth potential through diversified tech exposure. Key risks include concentration in seven stocks and market rotation away from mega-caps, while the bullish technical setup suggests potential for near-term recovery if AI momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
